References
- Y. Naritomi, S. Terashita, and A. Kagayama, Xenobiotica 34, 415 (2004).
- J.E. Hughes, C. Waldron, K.E. Bennett, and C. Cahir, Drugs Aging 40, 117 (2023).
- A.C. Doran, W. Burchett, C. Landers, G.M. Gualtieri, A. Balesano, H. Eng, A.L. Dantonio, T.C. Goosen, and R.S. Obach, Drug Metab. Dispos. 50, 1259 (2022).
- S. Hamada, Y. Ohno, T. Kojima, S. Ishii, J. Okochi, and M. Akishita, Geriatr. Gerontol. Int. 19, 513 (2019).
- M. Deodhar, S.B. Al Rihani, M.J. Arwood, L. Darakjian, P. Dow, J. Turgeon, and V. Michaud, Pharmaceutics 12, 846 (2020).
- W. Ren, Y. Liu, J. Zhang, Z. Fang, H. Fang, Y. Gong, and X. Lv, Int. J. Clin. Pharm. 42, 1190 (2020).
- T. Zhao, L. Mao, Z. Yu, Y. Hui, H. Feng, X. Wang, L. Lin, X. Fan, X. Chen, B. Wang, X. Cao, and C. Sun, Int. Immunopharmacol. 91, 107308 (2021).
- S. Yang, J. Hu, Y. Li, and Z. Zhao, Xenobiotica 49, 987 (2019).
- M. Hu, Y. Li, F. You, J. Bai, X. Fan, S. Zhao, Y. Sun, B. Wang, J. Hu, and Y. Li, Eur. J. Pharm. Sci. 154, 105518 (2020).
- F. Chen, H. Zou, P. Zhang, and Y. Yan, Xenobiotica 53, 231 (2023).
- X. Huang, M. Jia, Y. Liu, S. Wang, Y. Tang, X. Li, X. Jiang, Z. Wu, Y. Lou, and G. Fan, J. Pharm. Biomed. Anal. 220, 114947 (2022).
- H. Li, N.N. Liu, and Z.G. Peng, BMJ Open 10, e039700 (2020).
- P. Fasinu, P.J. Bouic, and B. Rosenkranz, Curr. Drug Metab. 13, 215 (2012).
- A. Parkinson, F. Kazmi, D.B. Buckley, P. Yerino, B.W. Ogilvie, and B.L. Paris, Drug Metab. Pharmacokinet. 25, 16 (2010).
- C.L. Crespi, in Advances in Drug Research, edited by B. Testa and U.A. Meyer (Academic Press, Amsterdam, 1995).
- M. Nakajima, S. Nakamura, S. Tokudome, N. Shimada, H. Yamazaki, and T. Yokoi, Drug Metab. Dispos. 27, 1381 (1999).
- K. Grime and R.J. Riley, Curr. Drug Metab. 7, 251 (2006).
- T. Bohnert, A. Patel, I. Templeton, Y. Chen, C. Lu, G. Lai, L. Leung, S. Tse, H.J. Einolf, Y.H. Wang, M. Sinz, R. Stearns, R. Walsky, W. Geng, S. Sudsakorn, D. Moore, L. He, J. Wahlstrom, J. Keirns, R. Narayanan, D. Lang, X. Yang, and International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Victim Drug-Drug Interactions Working Group, Drug Metab. Dispos. 44, 1399 (2016).
- S. Wang, X. Tang, T. Yang, J. Xu, J. Zhang, X. Liu, and L. Liu, Xenobiotica 49, 161 (2019).
- Y. Naritomi, F. Nakamori, T. Furukawa, and K. Tabata, Drug Metab. Pharmacokinet. 30, 21 (2015).
- Y. Chen, L. Liu, K. Nguyen, and A.J. Fretland, Drug Metab. Dispos. 39, 373 (2011).
- D. Zhang, M. Zhu, and W.G. Humphreys, Drug Metabolism in Drug Design and Development: Basic Concepts and Practice (John Wiley & Sons, New York, 2007).
- D. Pal and A.K. Mitra, J. Neuroimmune Pharmacol. 1, 323 (2006).
- C. for D.E. and Research, FDA. <https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers>.
- N. Chauret, A. Gauthier, and D.A. Nicoll-Griffith, Drug Metab. Dispos. 26, 1 (1998).
- Y. Cai, Q. Lin, Z. Jin, F. Xia, Y. Ye, Y. Xia, T.J. Papadimos, Q. Wang, G. Hu, J. Cai, and L. Chen, Chem. Res. Toxicol. 34, 103 (2021).